Drug design based on the structure of specific enzymes playing a role in carcinogenesis, e.g. tyrosine kinases, has been successful at identifying novel effective anticancer drugs. In contrast, no success has been achieved in drug design attempts, in which transcription factors or DNA-transcription factor complexes involved in the pathogenesis of human neoplasms were targeted. This failure is probably due to the fact that the mechanism of transcription regulation is probably too complex and still too inadequately understood to be a suitable target for drug design.
Introduction
There are many ways to define the crucial differences between cancer cells and their normal counterparts, from which they are derived. For several human tumors it is thought that the crucial carcinogenic event is the mutation of genes encoding proteins important in cell function. In most cases several mutations are necessary to transform a normal cell into a malignant one. The complex biological phenomena related to the abnormal behaviour of cancer cells, defined as the hallmarks of cancer [1] prognosis than hitherto used morphological and clinical approaches. A logical therapeutic implication of this concept is that, in principle, finding effective ways to modulate gene transcription should be an effective strategy to achieve redifferentiation and normalization of cancer cells, thus accomplishing therapeutic control of the neoplastic disease. In the present paper we summarize the evidence for the contention that certain naturally occurring agents can modulate transcriptional regulation, and we proffer the argument that such modulation might be a mechanism which may be profitably exploited in new anticancer drug development.
Consequence of alteration of transcriptional regulation for carcinogenesis
A growing body of data indicates that the deregulation of transcription factors can be crucial in the pathogenesis of different tumors. Many translocations that are typical of specific neoplastic disease like most leukemias and sarcomas involve chimeric proteins encoded by fusion genes that represent the pathogenetic initiating factors in the carcinogenesis process. These chimeric proteins, which can regulate gene transcription, consist of two proteins or protein fragments, which themselves can be transcription factors. Chimeric proteins often maintain the ability of the constituent transcription factors to bind to DNA and transactivate gene transcription, even though they elicit abnormal regulation. For some tumors the precise cascade of events from gene translocation to change of cell phenotype is only partially elucidated. In some cases the deregulation of a tyrosine kinase is oncogenic, as in the case of chronic myeloid leukaemia expressing the Bcr-Abl fusion protein. In other cases the key element is a transcription factor that works in an anomalous fashion [2] . In several sarcomas the deregulated transcription factor is the crucial cancer-initiating event ultimately leading to the malignant phenotype [3] [4] [5] [6] [7] [8] , implying that such a factor is a potential target for specific and effective therapies for these diseases. As an example for this scenario table 1 shows the main translocations in human soft tissue sarcoma, which are responsible for the formation of fusion proteins acting as deregulated transcription factors.
Can small molecules modulate transcription factor function?
Many attempts have been directed at modifying gene transcription regulation in tumor cells. It has been known for a long time that aza-cytidine or its more specific analogue aza-deoxy-cytidine modify regulation of gene transcription by inhibiting DNA methylases [9] . A large body of data supports the notion that the differentiationinducing and antileukemic effects of these compounds is related to a change of the methylation status of the promoters of several genes, that ultimately results in cell death/differentiation depending on the cellular model. This mechanism is the basis for the clinical use of these compounds in the therapy of some haematological malignancies [10, 11] . Another class of compounds that are under clinical investigation are the histone deacetylase (HDAC) inhibitors [12] . Convincing experimental evidence exists that the acetylation status of histones H3 and H4 and other nuclear proteins, including p53, affect the transcriptional regulation of cancerrelated genes. Thus HDAC inhibitors may exert efficacy by modifying the altered pattern of gene expression of cancer cells. Both, inhibitors of DNA methylation and of histone deacetylases, have shown significant biological and therapeutic effects against some neoplasms [10] [11] [12] . Their use in therapy is usually rationalised by the fact that carcinogenesis is associated with epigenetic events, not because they alter the transcriptional regulation of specific genes. Yet modification of the methylation or acetylation status of DNA and chromatin is unlikely leading to a specific anti-cancer effect. Inhibition of DNA methylation and histone deacetylation probably modifies the expression of a large number of genes, possibly including some mechanistically related to carcinogenesis or tumor progression, but also some related to normal cell function. Such compounds are potentially interesting as they engage a mode of action different from that of conventional anticancer drugs. But as their mechanism is not cancer-specific, their therapeutic index is necessarily limited. Nevertheless preclinical data supports the contention that inhibitors of DNA methylase or histone deacetylase can enhance the activity of other anticancer drugs by modifying resistance mechanisms. These findings provide the rational for ongoing clinical trials aimed at evaluating DNA-methylase and HDAC inhibitors in combination with other antineoplastic drugs.
The effect of cytotoxicants on transcription factors
The precise mechanism of action of most antitumor drugs has not yet been fully elucidated. For example, the reason why cisplatin is selectively effective against testicular cancer remains unresolved. None of the explanations that have been proposed so far have been supported by convincing data. For example, it has been suggested that the deficiency of some components of the DNA repair machinery, like the proteins XPA, involved in nucleotide excision repair mechanisms, e.g. XPA, a characteristic feature of testicular cancer, is the biochemical basis for the selective cytotoxicity of cisplatin [13] [14] [15] . However, this hypothesis is inconsistent with the fact that cells deficient in XPA are also very susceptible to DNA-alkylating agents such as L-PAM and nitrogen mustard [16] , whilst this does not appear to be the case for testicular cancer. One might argue that the real mechanism by which cisplatin exerts its cytotoxicity, highly selective for testicular cancer and reasonably selective for other human malignancies, e.g. ovarian cancer, is related to its ability to block the transcription of genes essential for the maintenance of these tumors. It is likely that DNA interacting drugs such as cisplatin, which forms DNA-intra and DNAinterstrand crosslinks, modify DNA structure such as to render some consensus sequences for the binding of transcription factors unrecognizable, thus leading to alterations of transcriptional regulation. There are reports indicating that high concentrations of cisplatin or other DNA interacting agents, e.g. doxorubicin, prevent the binding of transcription factors to specific consensus sequences in vitro [17, 18] .
However the relevance of these findings has been questioned because the supporting data has solely been obtained in vitro using concentrations of drugs that are much higher than those present in vivo in the biophase after treatment with tolerable doses.
Therefore the interference by this type of drug with transcription factor -DNA interactions, whilst biochemically intriguing, is probably not an antitumor mechanism of action in vivo. Likewise DNA methylating drugs such as temozolomide pose puzzling mechanistic dilemmas. Temozolomide, the best available chemotherapy for CNS tumors [19] [20] [21] have a much greater probability of response and survival after temozolomide treatment than glioma patients expressing AGT [22, 23] . This finding intimates that alkylation of O 6 -guanine is important for the action of temozolomide. But why should temozolomide-mediated methylation of guanine be so cytotoxic and render some tumors selectively sensitive to this drug? Many years ago we made the observation that replacing guanine with O 6 -methylguanine can modify the recognition of transcription factors [24] . Whether this might be a potential mechanism rendering some tumors selectively sensitive to methylating agents has not elucidated. But it is somewhat perplexing that a relatively "soft" DNA damaging agent producing only DNA methylation is much more effective against glioblastoma than compounds that cause much more severe DNA damage, i.e. DNA crosslinking agents. This finding suggests that temozolomide alters some events regulating gene expression rather than generally blocks DNA function.
Whilst all of these observations do not allow firm conclusions to be made, they suggest tentatively that the mechanism of antitumor specificity of some cytotoxic anticancer drugs is not due to their ability to inhibit DNA synthesis, but that cellspecific regulatory mechanisms are involved, one of these possibly being the regulation of gene transcription.
Marine compounds as modulators of gene transcription
One of the most potently cytotoxic natural products ever tested in panels of murine tumors and human tumor xenografts is ET-743 (Yondelis TM , Trabectedin).
This compound which is isolated from the sea squirt Ecteinascidia turbinata, a tunicate that grows on the mangrove roots throughout the Caribbean sea [25] , is a tetrahydroisoquinoline alkaloid that binds to the minor groove of DNA and subsequently forms covalent adducts by reacting with N2 of guanine to its carbinolamine moiety [26, 27] . Experiments in cells in vitro [28] suggest that ET-743 at concentrations that are pharmacologically reasonable (i.e. in the nM range) can specifically affect gene transcription in a promoter-dependent fashion [29, 30] . We transcription [29] . Interestingly inhibition was obtained when cells were exposed to ET-743 at concentrations of 10-100 nM, whereas it was not observed using other DNA binding drugs at much higher concentrations, typically 10 M. The data obtained with different promoters indicates that the effect was rather specific and certainly not due to a PolII inhibition. Other studies involving run on experiments in isolated NIH-3T3 nuclei confirmed the effects of ET-743 on the transcription of endogenous genes. These studies do not support the notion that the effects of ET-743
were the consequence of a general inhibition of transcription, as only a fraction of genes was affected. Some of these genes, like MDR1, c-jun, H2B or H4, contain functionally important CCAAT-boxes. However some genes that were affected, like c-fos, did not contain CCAAT-boxes, indicating that the effects of ET-743 were not specific for NF-Y but that other transcription factors were inhibited. Further studies were performed to investigate the effect of ET-743 on the promoters of genes (cyclin E, E2F1, TK, DHFR, cyclin A, cdc2 and cyclin B2) that regulate the cell cycle by using NIH-3T3 fibroblasts stably transfected with reporter vectors, containing either the CAT or luciferase genes, together with the thyromycin resistance containing vector [31] . Cells synchronized in G0 were stimulated to grow by serum addition, and at several time points the transcriptional activity of these promoters were studied in untreated and ET-743 treated cells. ET-743 caused a strong inhibition of cyclin B2 already at 1 nM, which might explain the G2 blockade induced by the drug. As far as G1/S promoters TK and DHFR are concerned, they were clearly inhibited, whereas cyclin E was increased at 4 out of 5 time points. Other promoters were not significantly affected. These data corroborate the idea that ET-743 is not a general inhibitor of transcription, but that it acts preferentially on some promoters by inhibiting or inducing their activity [31] . The conclusion is also supported by gene Although we have no formal demonstration that the antitumor activity of ET 743 is related to its effects on transcriptional regulation, we can exclude that it acts by inhibiting DNA synthesis. In fact the activity of ET-743 was unrelated to the rate of cell proliferation, and it was particularly high for cells in G1 or quiescent cells like monocytes and macrophages. Recently ET-743 was reported to have antiinflammatory properties, a mechanistic feature that seems related to modulation of expression of some cytokines and chemokines by monocyte and tumor-associated macrophages, that may influence tumor growth and angiogenesis [35] .These results intimate the intriguing possibility that compounds such as ET-743 may exert antitumor activity at the transcriptional level by modulating host-mediated events, e.g. inflammation and angiogenesis. In this context it seems pertinent to mention that much research is ongoing to identify compounds which inhibit HIF1 alpha, a transcription factor that is induced by hypoxia and promotes angiogenesis by activating the transcription of angiogenic factors like VEGF.
NF-kB as a target of naturally occurring agents
Nuclear factor of kB, commonly referred to as NF-kB, has an important role in various physiological processes as well as in the development of many human diseases including immune-related diseases and cancer. For this reason it has attracted a lot of research interest during the last decade [36] . NF-kB is implicated in regulating many fundamental pathways including immune response, cell growth and survival. Its deregulation is often associated with various malignancies and can also lead to death through different mechanisms [37, 38] . NF-kB is not a single protein but consists of at proteasome. The processing of the p100 complexes leads to the formation of p52/p52
homodimers, which form a complex with the nuclear coactivator Bcl3 to regulate gene expression, and p52/RelB heterodimers, which can directly regulate gene expression [39] . The fundamental role of NIK in this pathway and the necessity of its stabilization provide possible explanations for the reason why activation of the noncanonical pathway is delayed compared to the classical pathway, and why it can be inhibited by protein synthesis inhibitors and proteasome inhibitors [37] like bortezomib, a drug with demonstrated activity in human multiple myeloma [40, 41] .
In most normal cells the constitutive level of p100 processing is nearly undetectable, while it has been shown to be relatively high in many malignancies, mostly myelomas and leukemias. Intriguingly p100 knockout mice do not seem to develop any notable malignancies. Recent studies also showed that inhibition of p100 processing by downregulation of p100 expression causes a significant reduction in tumor cell proliferation, thus eliciting interest in the possible role of this new pathway in cancer therapy. Lately, much interest has been raised in natural products which can inhibit NF-kB [38, 42, 43] . These substances (see Table 2 ) are now under intense scrutiny for their potential use in oncology as single agents or as adjuvants of commonly used chemotherapeutics. The success achieved with the proteasome inhibitor bortezomib in the therapy of myeloma has increased the desire to identify new compounds directed to elements of the NF-kB pathway. It has been proposed that the selectivity of bortezomib for myelomas is related to its ability to inhibit the degradation of IKK, thus inhibiting the nuclear translocation of NF-kB.
Many of the naturally occurring NFkB inhibitors (Table 2) are ingested with the diet, and thus might prove to be relatively safe and well tolerated. Potential safety is a promising aspect of this type of agents, some of which exert putative cancer chemopreventive properties in experimental model systems. Epidemiological evidence hints at the possibility that people consuming sufficiently large amounts of these substances with their diet have a reduced risk of developing malignancies, especially those of the gastro-intestinal tract [44] [45] [46] [47] . Overall the ability of a large number of natural products to act on NF-kB represents an attractive opportunity for the identification of novel drugs active in the prevention and/or therapy of malignancies. It needs to be emphasized that most available data on these natural products has been obtained in vitro, thus without consideration of their metabolism in vivo. This is an important point because most natural products listed in table 2, when administrated in vivo, undergo rapid biotransformation. In most cases these compounds undergo enzyme-catalyzed conjugation with glucuronic acid, activated sulphate or glutathione generating pharmacologically inactive metabolites. The possibility cannot be excluded that molecules may be identified that do not undergo phase II drug metabolism, or that molecules can be chemically altered so as to prevent rapid in vivo biotransformation. Certainly the semi-synthetic approach to obtain potent inhibitors that are sufficiently stable to reach the tumor target in vivo in sufficient amounts to exert biological effects is an attractive area of research in the development of novel compounds acting on NF-kB.
Conclusions
In the last decade experimental and clinical oncologists have started to develop anticancer drugs that have been designed to inhibit specific targets relevant to cancer cell growth, survival and angiogenesis [48, 49] . Table 2 : Plant-derived natural NF-kB inhibitors Figure 1 . Activation of NF-kB by the classical pathway (left) and the alternative pathway (right). Signaling through TNFR, IL-1R, or Toll-like receptors (TLR) activates the classical NF-kB pathway involving predominantly the  and  subunits of the IKK complex. Nuclear translocatio n and DNA-binding of p50-RelA heterodimers is accomplished through IkB phosphorylation and ubiquitin-dependent proteasomal degradation. Membrane-bound LT12 heterodimers, CD40, and BAFF, on the other hand, activate via their respective receptors the kinases NIK and IKK. Phosphorylation of p100 results in the processing of the precursor to the p52 subunit and nuclear accumulation of p52-RelB heterodimers. There is significant cross talk since signaling through the LTR, for instance, also results in the induction of RelA complexes and LPS can also trigger the processing of p100 to p52. It is likely that the two pathways activate distinct sets of genes.and BAFF, on the other hand, activate via their respective receptors the kinases NIK and IKK. Phosphorylation of p100 results in the processing of the precursor to the p52 subunit and nuclear accumulation of p52-RelB heterodimers. There is significant cross talk since signaling through the LTR, for instance, also results in the induction of RelA complexes and LPS can also trigger the processing of p100 to p52. It is likely that the two pathways activate distinct sets of genes.
